Biodexa Pharmaceuticals's quarterly market cap
increased
from Dec. 2024 (€1,435.20 Mil) to Jun. 2025 (€13,689.60 Mil) and
increased
from Jun. 2025 (€13,689.60 Mil) to Dec. 2025 (€49,900.80 Mil).
Biodexa Pharmaceuticals's annual market cap
increased
from Dec. 2023 (€220.80 Mil) to Dec. 2024 (€1,435.20 Mil) and
increased
from Dec. 2024 (€1,435.20 Mil) to Dec. 2025 (€49,900.80 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Biodexa Pharmaceuticals's Enterprise Value for Today is €82,790.31 Mil.
Biodexa Pharmaceuticals (STU:5MP2) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Biodexa Pharmaceuticals Market Cap Related Terms
Biodexa Pharmaceuticals Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:5MP2 vs CASIF, OGEN, ELOX: Market Cap Comparison
For the Biotechnology subindustry, Biodexa Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biodexa Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biodexa Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Biodexa Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Biodexa Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biodexa Pharmaceuticals (STU:5MP2) has a Market Cap of €82,800.00 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Biodexa Pharmaceuticals and its competitors. According to the industry distribution chart, Biodexa Pharmaceuticals ranks #1374 out of 1431 companies in the Biotechnology industry, placing it in the top 96%.
Is Biodexa Pharmaceuticals' Market Cap too high?
Biodexa Pharmaceuticals' current Market Cap is €82,800.00 Mil. Based on the distribution chart, Biodexa Pharmaceuticals ranks #1374 out of 1431 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biodexa Pharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' Market Cap compare to CASIF and OGEN?
According to the Biotechnology industry distribution chart, Biodexa Pharmaceuticals ranks #1374 out of 1431 companies for Market Cap. This places Biodexa Pharmaceuticals in the lower half of its industry. The industry median Market Cap is 117.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Biodexa Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biodexa Pharmaceuticals's current Market Cap is €82,800.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Biodexa Pharmaceuticals (STU:5MP2) has a current Market Cap of €82,800.00 Mil. The stock's GF Value™ is €95,593.41, compared to a current price of €110,400.00 — trading 15.5% above its estimated fair value. The current Market Cap is €82,800.00 Mil. Biodexa Pharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Biodexa Pharmaceuticals (STU:5MP2), the current Market Cap is €82,800.00 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biodexa Pharmaceuticals (STU:5MP2) Overvalued in 2026?
Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued.
The current stock price of €110,400.00 is trading 15.5% above its estimated GF Value™ of €95,593.41.
Key valuation signals for STU:5MP2:
Market Cap: €82,800.00 Mil
GF Value™: €95,593.41 vs. price of €110,400.00 (15.5% above fair value)
No single metric tells the full story. See the STU:5MP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
10GF Score
Get the complete analysis for STU:5MP2
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:5MP2 has been successfully added to your 
